此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients (SPORE)

2026年11月10日 更新者:University of Utah

Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients is not yet established. This study will assess beliefs about the heritability of leiomyosarcoma (LMS) and other cancers, and attitudes toward germline testing among LMS patients.

研究概览

地位

招聘中

详细说明

This is a descriptive study to explore attitudes toward genomics and interest in receiving personal genetic information among patients with leiomyosarcoma (LMS). The study aims to:

  • Assess LMS patients' beliefs and attitudes about the heritability of LMS.
  • Assess LMS patients' interest in genetic testing and their preferences for receiving information about genetic testing.

Prior studies of cancer patients have found strong interest in germline genetic testing to inform personal and familial cancer risk. However, germline genetic testing is not widely recommended for patients diagnosed with LMS, and little is known about patients' beliefs about the heritability of LMS or their interest in genetic testing. This study will use a survey to assess beliefs about the heritability of LMS, interest in genetic testing, and preferences for receiving information about genetic testing.

Participants will be identified by querying the Enterprise Data Warehouse (EDW) and the Huntsman Tumor Registry, recruiting in clinics at the Huntsman Cancer Institute, receiving referrals from providers outside the Huntsman Cancer Institute, and through LMS patient support and advocacy organizations.

研究类型

观察性的

注册 (估计的)

400

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Utah
      • Salt Lake City、Utah、美国、84112
        • 招聘中
        • Huntsman Cancer Institute at the University of Utah
        • 接触:
        • 首席研究员:
          • Wendy K Kohlmann, MS

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population will be Patients with a confirmed or self reported diagnosis of LMS

描述

Inclusion

  • Living
  • Able to speak and read English or Spanish
  • Mentally competent
  • Age 18 or older

Exclusion

  • <18 years
  • Unable to read or write

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Patients with leiomyosarcoma

Electronic questionnaire assessing beliefs about the heritability of LMS and interest in genetic testing

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Beliefs about the heritability of Leiomyosarcoma
大体时间:up to 1 day from study enrollment

This outcome will describe LMS patients' beliefs about the heritability of LMS as well as other cancers, diseases, and physical traits. A five point Likert scale is used to classify conditions from totally inherited to totally environmental.

up to 1 day from study enrollment

次要结果测量

结果测量
措施说明
大体时间
Interest in germline genetic testing
大体时间:up to 1 day from study enrollment

This outcome will report interest in genetic testing for cancer predisposition for themselves as well as for other people such as family members, children, and the general public. Likert scales will be used to assess general interest in genetics and genetic testing in general. Interest in genetic testing will also be assessed with questions about when in the lifespan testing should be offered and for which types of conditions.

up to 1 day from study enrollment

其他结果措施

结果测量
措施说明
大体时间
Preferences for receiving information about genetic testing.
大体时间:up to 1 day from study enrollment

This outcome will report the count of participants who self reported sources for genetic testing information as helpful.

Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported >5 on this scale are considered to have found the source for genetic testing information as helpful.

This outcome will assess information presented in tables and graphs and information presented numerically .

up to 1 day from study enrollment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Wendy Kohlmann, MS、Huntsman Cancer Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月1日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2025年3月7日

首先提交符合 QC 标准的

2025年3月7日

首次发布 (实际的)

2025年3月13日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 165523
  • 1P50CA272170-01 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Deidentified IDP will be shared with the University of Michigan Rogel Cancer Center for data analysis.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅